Group 1: New Stock Offerings - The tender offer for Shangwei New Materials (688585) is open from September 29, 2025, to October 28, 2025[1] - Huajian Group (600629) announced significant updates on October 22, 2025[1] - ST Dongyi (002713) reported on October 22, 2025, regarding its stock status[1] Group 2: Stock Volatility Alerts - Dayou Energy (600403) experienced severe abnormal fluctuations, with updates on October 22 and 23, 2025[1] - Multiple companies, including Tianpu Co. (605255) and Guangming Real Estate (600708), reported abnormal trading activities on October 23, 2025[1] - ST Nanzhi (002305) and ST Aowei (002231) are under scrutiny for unusual market behavior as of October 23, 2025[1]

Core Viewpoint - The A-share market continues to see an upward trend in flu-related stocks, driven by rising flu activity and concerns over a potentially severe flu season this year [1] Group 1: Stock Performance - Hendi Pharmaceutical has seen a rise of over 18% - Dori Pharmaceutical has increased by over 11% - Guangji Pharmaceutical and Te Yi Pharmaceutical have hit the 10% daily limit up - Chenxin Pharmaceutical has also increased by over 6% - Notably, Guangji Pharmaceutical has achieved two consecutive limit-up days [1] Group 2: Flu Activity and Expert Insights - The China CDC reported that flu activity in northern provinces is currently low, while southern provinces are experiencing an increase - Overall, respiratory disease incidence is showing a slow upward trend nationwide - Experts indicate that the main flu strain this year is likely to be the H3N2 subtype, which was largely absent last year, leading to lower immunity levels in the population - Many experts believe that this year's flu season may arrive earlier and result in a higher number of infections [1]

Group 1 - The company has cumulatively repaid RMB 100 million of temporarily supplemented working capital as of October 21, 2025 [1] - The company decided to use up to RMB 100 million of idle raised funds to temporarily supplement working capital to improve fund utilization efficiency, increase company earnings, reduce financial costs, and lower operational costs [1] - The temporary use of idle funds is limited to a period not exceeding 12 months from the date of board approval, with a commitment to return the funds to the special account if necessary [1] Group 2 - As of the announcement date, the company has fully repaid the idle raised funds used for temporary working capital [2] - The company has notified its sponsor institution and the sponsor representative about the repayment of the raised funds [2]

证券代码：688189 证券简称：南新制药 公告编号：2025-048 湖南南新制药股份有限公司 关于提前归还临时用于补充流动资金的募集资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ■ 2025年10月21日，公司将上述暂时补充流动资金的10,000.00万元提前归还至募集资金专用账户。截至本 公告披露日，公司用于暂时补充流动资金的闲置募集资金已全部归还。公司已将上述募集资金的归还情 况通知了公司的保荐机构及保荐代表人。 特此公告。 湖南南新制药股份有限公司董事会 2025年10月22日 ● 截至2025年10月21日，公司已累计归还临时补充流动资金的闲置募集资金人民币10,000.00万元。 一、募集资金临时补充流动资金情况 ■ 湖南南新制药股份有限公司（以下简称"公司"）于2024年12月11日召开第二届董事会第十四次会议和第 二届监事会第十二次会议，审议通过了《关于使用部分闲置募集资金暂时补充流动资金的议案》。为提 高募集资金使用效率，增加公司收益，减少公司财务费用，降低公司运营成本，维护公 ...

New Stock Offerings - The tender offer for Shangwei New Materials (688585) is open from September 29, 2025, to October 28, 2025[1] - BoRui Pharmaceutical (688166) and Nanxin Pharmaceutical (688189) announced significant abnormal fluctuations on October 10, 2025[1] - Tianpu Co., Ltd. (605255) and Pingtan Development (000592) issued announcements on October 21, 2025[1] Market Alerts - Multiple companies, including AnTong Holdings (600179) and GuoXin New Energy (600617), issued announcements on October 21, 2025, regarding their stock performance[1] - A total of 20 companies reported abnormal fluctuations in their stock prices, indicating potential volatility in the market[2] - The report highlights the importance of monitoring these fluctuations for investment strategies and risk management[2]

湖南南新制药股份有限公司 关于提前归还临时用于补充流动资金的募集资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 截至 2025 年 10 月 21 日，公司已累计归还临时补充流动资金的闲置募集 资金人民币 10,000.00 万元。 证券代码：688189 证券简称：南新制药 公告编号：2025-048 一、募集资金临时补充流动资金情况 湖南南新制药股份有限公司（以下简称"公司"）于 2024 年 12 月 11 日召开 第二届董事会第十四次会议和第二届监事会第十二次会议，审议通过了《关于使 用部分闲置募集资金暂时补充流动资金的议案》。为提高募集资金使用效率，增 加公司收益，减少公司财务费用，降低公司运营成本，维护公司和股东利益，在 确保募集资金投资计划正常进行的前提下，公司决定使用不超过人民币 10,000.00 万元（含本数）闲置募集资金暂时补充流动资金，使用期限为自董事 会审议通过之日起不超过 12 个月，到期归还至募集资金专用账户。在此期间如 遇募集资金专用账户余额不能满足募集资金正常支付的 ...

New Stock Issuance - Xi'an Yicai (787783) issued at a price of 8.62[1] - Changjiang Energy Technology (920158) issued at a price of 5.33[1] Equity Market Alerts - Tender offer for Shangwei New Materials (688585) from September 29, 2025, to October 28, 2025[1] - Significant abnormal fluctuation reported for Nanjing New Pharmaceutical (688189) with a recent announcement on October 10, 2025[1] Recent Announcements - Multiple companies reported significant fluctuations, including ST Yanzhen (603389) with a recent announcement on October 16, 2025[1] - ST Hengjiu (002808) reported a fluctuation with an announcement on October 16, 2025[1] Trading Alerts - A total of 50 companies reported trading alerts with varying degrees of fluctuation, with the highest being 9889 for ST Jianyi (002789) on October 14, 2025[1] - The lowest fluctuation reported was 1,010 for ST Xinyuan (300472) on October 13, 2025[1]

Core Viewpoint - Nanjing Pharmaceutical's stock has experienced significant fluctuations, with a year-to-date increase of 23.39% but a recent decline of 11.32% over the past five trading days, indicating volatility in investor sentiment and market performance [1][2]. Group 1: Stock Performance - As of October 16, Nanjing Pharmaceutical's stock price is 8.07 CNY per share, with a market capitalization of 2.214 billion CNY [1]. - The stock has seen a net outflow of 6.2132 million CNY in principal funds, with large orders accounting for 5.73% of total buying and 16.77% of total selling [1]. - The stock has appeared on the daily trading list seven times this year, with the most recent appearance on October 9, where it recorded a net buying of -3.8709 million CNY [1]. Group 2: Financial Performance - For the first half of 2025, Nanjing Pharmaceutical reported a revenue of 61.8463 million CNY, a year-on-year decrease of 71.28%, and a net profit attributable to shareholders of -40.0023 million CNY, a decline of 493.23% [2]. - The company has not distributed any dividends in the past three years, with a total payout of 40.74 million CNY since its A-share listing [3]. Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders increased by 7.02% to 9,464, while the average circulating shares per person decreased by 6.56% to 28,994 shares [2]. - Among the top ten circulating shareholders, Dazheng Jingheng Mixed A holds 2.9738 million shares, with no change in the number of shares held compared to the previous period [3].

New Stock Issuance - New stock issuance includes 泰凯英 (code: 920020) at an issuance price of 7.50 and 超颖电子 (code: 732175) at 17.08[1] Equity Market Alerts - 上纬新材 (code: 688585) is undergoing a tender offer from September 29, 2025, to October 28, 2025[1] - 科思科技 (code: 688788) and 博瑞医药 (code: 688166) have recent announcements dated September 26, 2025, and October 10, 2025, respectively[1] - 南新制药 (code: 688189) reported severe abnormal fluctuations on October 10, 2025[1] Trading Alerts - A total of 50 stocks have trading alerts with the latest announcements on October 15, 2025, including 国光连锁 (code: 605188) and 中持股份 (code: 603903)[1] - The lowest trading alert price recorded is 1,116 for 赛恩斯 (code: 688480)[1]

Core Viewpoint - Nanjing Pharmaceutical has experienced significant stock price fluctuations, with a year-to-date increase of 21.71% but a recent decline of 29.99% over the past five trading days, indicating volatility in investor sentiment and market performance [2]. Group 1: Stock Performance - As of October 15, Nanjing Pharmaceutical's stock price rose by 2.05% to 7.96 CNY per share, with a trading volume of 25.54 million CNY and a turnover rate of 1.18%, resulting in a total market capitalization of 2.18 billion CNY [1]. - The stock has seen a year-to-date increase of 21.71%, but has declined by 29.99% in the last five trading days, 38.39% in the last 20 days, and 21.11% in the last 60 days [2]. Group 2: Financial Performance - For the first half of 2025, Nanjing Pharmaceutical reported a revenue of 61.84 million CNY, a year-on-year decrease of 71.28%, and a net profit attributable to shareholders of -40.00 million CNY, reflecting a significant decline of 493.23% [3]. - The company has distributed a total of 40.74 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [4]. Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders increased by 7.02% to 9,464, while the average circulating shares per person decreased by 6.56% to 28,994 shares [3]. - Among the top ten circulating shareholders, Dazheng Jingheng Mixed A ranks as the fourth largest, holding 2.97 million shares, unchanged from the previous period [4]. Group 4: Company Overview - Nanjing Pharmaceutical, established on December 27, 2006, and listed on March 26, 2020, focuses on the research, production, and sales of antiviral and infectious disease treatment drugs, as well as medications for major diseases like cardiovascular diseases and diabetes [2]. - The company operates in the pharmaceutical and biotechnology sector, specifically in chemical pharmaceuticals and formulations, with its main business revenue derived entirely from chemical drug formulations [2].